ACDN-01 not checked

Ascidian Therapeutics, Inc

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“ACDN-01 is an AAV-based vector carrying a DNA construct encoding for an ABCA4 RNA exon editor. One time administration is via subretinal injection.”In the company’s words, NCT06467344 on ClinicalTrials.gov
Tested for
Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
Main trialPhase 1/2
“This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.”In the company’s words, NCT06467344 on ClinicalTrials.gov

Other drugs for Stargardt Disease

All 11 drugs for Stargardt Disease

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 1 Aug 2030 Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow ACDN-01

Following is part of Solo: you see every change to ACDN-01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in